Monotherapy with interferon-α, or combination therapy with interferon-α, interleukin-2 and 5-fluorouracil for metastatic renal cell carcinoma

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [41] Interleukin-2 (IL-2), interferon-α (IFN-α), 5-fluorouracil (5-FU) and vinblastine (VBL) for treatment of metastatic renal cell carcinoma (MRCC).: A prospective phase II study.
    Rubinov, R
    Gez, E
    Haim, N
    Kuten, A
    Meritick, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 424S - 424S
  • [42] Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma
    Noda, T.
    Nagano, H.
    Takemasa, I.
    Yoshioka, S.
    Murakami, M.
    Wada, H.
    Kobayashi, S.
    Marubashi, S.
    Takeda, Y.
    Dono, K.
    Umeshita, K.
    Matsuura, N.
    Matsubara, K.
    Doki, Y.
    Mori, M.
    Monden, M.
    BRITISH JOURNAL OF CANCER, 2009, 100 (10) : 1647 - 1658
  • [43] Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma
    T Noda
    H Nagano
    I Takemasa
    S Yoshioka
    M Murakami
    H Wada
    S Kobayashi
    S Marubashi
    Y Takeda
    K Dono
    K Umeshita
    N Matsuura
    K Matsubara
    Y Doki
    M Mori
    M Monden
    British Journal of Cancer, 2009, 100 : 1647 - 1658
  • [44] COMBINATION OF INTERLEUKIN-2 AND GAMMA-INTERFERON IN METASTATIC RENAL-CELL CARCINOMA
    ESCUDIER, B
    FARACE, F
    ANGEVIN, E
    TRIEBEL, F
    ANTOUN, S
    LECLERCQ, B
    BRANDELY, M
    ABOUDARAM, A
    NITENBERG, G
    HERCEND, T
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) : 724 - 728
  • [45] Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
    Ellerhorst, JA
    Sella, A
    Amato, RJ
    Tu, SM
    Millikan, RE
    Finn, LD
    Banks, M
    Logothetis, CJ
    CANCER, 1997, 80 (11) : 2128 - 2132
  • [46] Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
    Négrier, S
    Caty, A
    Lesimple, T
    Douillard, JY
    Escudier, B
    Rossi, JF
    Viens, P
    Gomez, F
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) : 4009 - 4015
  • [47] A randomized phase II trial of interleukin-2 and interferon- plus bevacizumab versus interleukin-2 and interferon- in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1
    Donskov, Frede
    Jensen, Niels Viggo
    Smidt-Hansen, Torben
    Brondum, Line
    Geertsen, Poul
    ACTA ONCOLOGICA, 2018, 57 (05) : 589 - 594
  • [48] Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro
    Yin, Haipeng
    Xie, Fengxiang
    Zhang, Jiao
    Yang, Yongmei
    Deng, Biping
    Sun, Jintang
    Wang, Qingjie
    Qu, Xun
    Mao, Haiting
    CANCER LETTERS, 2011, 306 (01) : 34 - 42
  • [49] Metastasis renal cell carcinoma:: Therapy alternative to interferon-α
    Staehler, Michael
    AKTUELLE UROLOGIE, 2008, 39 (02) : 92 - +
  • [50] Low-dose interleukin-2 (IL-2) in combination with interferon-A (IFN) and 5-fluorouracil (5-FU) for metastatic renal cell carcinoma (MRCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 286 - 286
12345